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Symptom cluster, healthcare use and mortality in patients with severe
chronic obstructive pulmonary disease
Soo Kyung Park and Janet L Larson
Aims and objectives. To examine how subgroups of patients with chronic
obstructive pulmonary disease, identified by ratings of symptoms (dyspnoea, anxi-
ety, depression and fatigue), affect healthcare use and mortality.
Background. People with chronic obstructive pulmonary disease often experience
multiple symptoms. The importance of multiple symptoms and symptom clusters
has received increased attention. However, little is known about symptom clusters
and their effect on healthcare use and mortality in this population.
Design. Descriptive cross-sectional study.
Methods. This secondary data analysis used data from the National Emphysema
Treatment Trial. Participants (n = 597) had severe chronic obstructive pulmonary
disease. Descriptive and inferential statistics were used to analyse the data that
were drawn from structured interviews, questionnaires and clinical measures.
Results. Three subgroup clusters emerged based on four symptom ratings. Mean
age, proportion with higher education, proportion using oxygen, disease severity,
exercise capacity and quality of life differed significantly between subgroups. Par-
ticipants with high levels of symptoms used healthcare services more and were
more likely to have died at the five-year follow-up than those with low levels of
symptoms. Symptom cluster subgroups had more significant relationship with
mortality than single symptoms.
Conclusion. Patients with high levels of symptoms require greater clinical
attention.
Relevance to clinical practice. Understanding subgroups of patients, based on
symptom ratings and their adverse effect on outcomes, may enable healthcare
providers to assess multiple symptoms and identify subgroups of patients at risk
of increased healthcare use and mortality. Targeting modifiable symptoms within
the cluster may be more beneficial than focusing on a single symptom for certain
health-related outcome.
Key words: chronic obstructive pulmonary disease, healthcare use, mortality,
National Emphysema Treatment Trial, symptoms
What does this paper contribute
to the wider global clinical
community?
• Patients with high levels of
symptoms require greater clinical
attention.
• Targeting modifiable symptoms
within the cluster may be more
beneficial than focusing on a sin-
gle symptom to improve survival
in people with chronic obstruc-
tive pulmonary disease (COPD).
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Introduction
In 2008, chronic obstructive pulmonary disease (COPD)
was ranked as the third leading cause of death in the USA
(Mini~no et al. 2010). Mortality from COPD is still substan-
tial, although the mortality rate in people with COPD has
declined since 1999 (Ford et al. 2013). Overall mortality
from COPD was reported to be 44% and, in severe cases
of the disease, to be 71% in a 22-year cohort study that
was conducted in the USA (Mannino et al. 2003). Another
20-year cohort study, conducted in Sweden, reported 54%
overall mortality in patients with COPD and 81% in those
with severe disease (Lundb€ack et al. 2009).
People with COPD use substantial medical resources at
great cost. In 2010, COPD care was projected to cost $499
billion, more than a quarter of which was attributed to hos-
pital care alone (National Institutes of Health, National
Heart, Lung, & Blood Institute 2013). In 2006, COPD
accounted for 672,000 hospital admissions (American Lung
Association 2013), which represents 52–70% of direct per
patient costs (Foster et al. 2006). Besides treatment costs,
hospital admissions have a negative effect on the survival
rates of patients with COPD (Almagro et al. 2002).
Research studies of people with COPD have focused
mainly on single symptoms. However, people with COPD
rarely experience just one symptom in the course of their
disease. Rather, they experience multiple symptoms that
adversely affect their quality of life and functional status
(Blinderman et al. 2009, Park et al. 2012). The concept of
symptom clusters, that is, two or more related concurrent
symptoms, offers a new approach to symptom assessment
and management (Kim et al. 2005). It is now known that
certain symptom clusters and high symptom burden can
affect clinical outcomes, such as functional status, quality
of life or level of physical activity in people with a variety
of chronic diseases (Miaskowski et al. 2006, Motl &
McAuley 2009, Aktas et al. 2010). Furthermore, healthcare
use and mortality have been examined in the literature as
an outcome of symptom clusters in people with acute coro-
nary syndrome, heart failure and a history of lung cancer
(Lee et al. 2010, Riegel et al. 2010, Cheville et al. 2011,
Hwang et al. 2012). These studies found that people with
certain symptom clusters had significantly higher mortality
rates (Riegel et al. 2010, Hwang et al. 2012). One study,
however, found no association between visits to an emer-
gency department (ED) and symptom clusters in people
with acute coronary syndrome (Riegel et al. 2010).
Overall, little is known about the relationship between
symptom clusters and healthcare use and mortality in people
with COPD. Worsening symptoms are main reason why
patients with COPD seek treatment or hospital care. One
study has shown that dyspnoea, the main symptom experi-
enced by people with COPD, was a stronger predictor of
mortality than disease severity (Nishimura et al. 2002). Thus,
the effect of symptom clusters on healthcare use and mortal-
ity in people with COPD should be examined: Symptom clus-
ters could be a modifiable factor to decrease healthcare use
and morality and may be a stronger predictor of adverse out-
comes than single symptoms. In this study, we formed sub-
groups based on four symptoms (dyspnoea, anxiety,
depression and fatigue) that are commonly experienced by
people with COPD and examined their effect on healthcare
use and mortality. By this approach, healthcare providers will
be better able to identify patients who are likely to use more
healthcare services and are at risk of higher mortality.
Background/Literature review
Symptoms and healthcare use in patients with COPD
In the past, researchers have examined the relationship
between single symptoms and healthcare use in people with
COPD. Dyspnoea has been associated with COPD-related
hospital admissions (Schembri et al. 2009) and has also
independently predicted exacerbation-related hospital
admissions and visits to the ED (Fan et al. 2007). Anxiety
was related to relapse within one month after emergency
treatment in patients with asthma or COPD (Dahlen &
Janson 2002). However, another study found no association
between anxiety and hospital admission in patients with
severe COPD (Fan et al. 2007). Depression was found to be
an independent predictor of hospital admissions for acute
exacerbation at follow-up one year poststudy (Papaioannou
et al. 2013). Dahlen and Janson (2002), who also examined
ED patients with asthma or COPD, found that depression
was related to relapse within one month after emergency
treatment. In contrast, another study found no relationship
between depression and hospital admission in patients with
severe COPD (Fan et al. 2007). Ng et al. (2007) also found
that depression was not significantly associated with hospi-
tal readmission in an adjusted model. Finally, the literature
contains no information on the relationship between fatigue
and healthcare use in people with COPD.
Symptoms and mortality in patients with COPD
Past studies of people with COPD have reported the rela-
tionship of single symptoms with mortality. Dyspnoea has
been found to be predictive of survival in patients with
COPD (Nishimura et al. 2002, Esteban et al. 2008,
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Schembri et al. 2009) and to be superior to forced expira-
tory volume in one second (FEV1) in predicting death
(Nishimura et al. 2002). All-cause mortality and risks of
cardiovascular mortality were significantly increased
among patients with severe dyspnoea (Figarska et al.
2012). Unlike dyspnoea, anxiety has not been associated
with mortality in the literature (Fan et al. 2007, Ng et al.
2007). Reports on the relationship between depression and
mortality are in conflict. Several studies have reported a
significant association between depression and an increased
risk of mortality (Fan et al. 2007, Ng et al. 2007, de Voo-
gd et al. 2009, Papaioannou et al. 2013). Yet, other stud-
ies have reported just the opposite (Yohannes et al. 2002,
2005, Stage et al. 2005). As for fatigue, little is known
about relationship between fatigue and mortality in people
with COPD. Overall, no studies have examined how
symptom clusters affect healthcare use and mortality in
people with COPD.
Purpose
The purpose of this study was to determine how subgroups
of patients with COPD, identified by their ratings of symp-
toms (dyspnoea, anxiety, depression and fatigue), differed
on healthcare use and mortality.
Methods
Design
Data from the National Emphysema Treatment Trial
(NETT) was used for this cross-sectional study. The NETT
study was conducted by the Centers for Medicare and Medic-
aid Services, the National Institutes of Health and the Agency
for Healthcare Research and Quality. Its design and method
have been described previously (National Emphysema Treat-
ment Trial Research Group 1999, Fishman et al. 2003). The
purpose of the NETT, an original randomised controlled
trial, was to evaluate the safety and effectiveness of lung
volume reduction surgery for people with emphysema.
Sample, settings and procedures
Patients were recruited for the NETT by self-referral or
they were referred by their physician. After the patients’
history and clinical information were reviewed for eligibil-
ity, those without contraindications to participation were
invited for testing. In all, 3777 patients were screened for
the NETT from 1998–2002 (National Emphysema Treat-
ment Trial Research Group 2003). To be included in the
study, individuals were required to have: (1) radiological
evidence of bilateral emphysema; (2) severe airflow obstruc-
tion and hyperinflation; and (3) participation in pulmonary
rehabilitation and attainment of preset performance goals
(National Emphysema Treatment Trial Research Group
1999). Individuals were excluded if they exhibited charac-
teristics that placed them at risk of perioperative morbidity
or mortality such as previous lung transplantation or con-
gestive heart failure within six months (National Emphy-
sema Treatment Trial Research Group 1999). All
participants completed 4–10 weeks of pulmonary rehabili-
tation before randomisation and six sessions of rehabilita-
tion after randomisation. A total of 1218 individuals
underwent randomisation. All participants at the 17 NETT
clinics were randomly assigned to either usual medical ther-
apy (n = 610) or usual medical therapy plus lung volume
reduction surgery (n = 608).
Baseline measurements were taken before randomisation.
Various measures were recollected at six months, at
12 months and yearly thereafter postrandomisation. The
NETT’s primary outcomes were mortality and maximum
exercise capacity two years after randomisation. For our
analysis, we included participants in the medical therapy
group (n = 610) who were aged 52–79 because the data set
did not provide ages for patients younger than 52 and older
than 79. Only those patients who had data for all variables
were included. We used baseline data for all study variables
except outcome variables. The NETT was approved by
each clinic’s institutional review board, and informed con-
sent was obtained from each participant.
Instruments
Dyspnoea
The University of California, San Diego, Shortness of Breath
Questionnaire (SOBQ) was used to measure dyspnoea. This
instrument, which comprises 24 items, measures shortness of
breath associated with 21 daily activities and limitations in
daily life. Of the 24 items, we used 21 for our analysis. Par-
ticipants answered each question on a scale of zero (‘none at
all’) to five (‘maximal or unable to do because of breathless-
ness’). Cumulative scores could range from 0 (‘best’)–105
(‘worst’). This instrument’s internal consistency (a = 0.96)
and concurrent validity with FEV1 (r = 0.50) have been
reported in the literature (Eakin et al. 1998). Internal consis-
tency for our study was Cronbach’s alpha = 0.94.
Anxiety
Anxiety was assessed with the state anxiety component of
the State-Trait Anxiety Inventory (STAI). This instrument
© 2014 John Wiley & Sons Ltd
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consists of 20 questions on a four-point scale: 1 (‘almost
never’), 2 (‘sometimes’), 3 (‘often’) and 4 (‘almost always’)
(Spielberger et al. 1983). Cumulative scores could range
from 20–80. Higher scores indicated higher levels of anxi-
ety. Test-retest reliability and concurrent validity have been
reported in the literature (Spielberger et al. 1983).
Depression
Depression was evaluated with the Beck Depression Inven-
tory (BDI), which comprises 21 items (Beck & Steer 1993).
In response to each item, participants were asked to select
one of four sentences that reflected how they felt over the past
two weeks. Responses were scored on a scale of 0–3. Cumu-
lative scores could range from 0–63. Higher scores indicated
a deeper level of depression. Test-retest reliability (r = 095)
has been reported (Fountoulakis et al. 2007). Concurrent
validity with the Center for Epidemiologic Studies’ Depres-
sion Scale has been reported (Kalichman et al. 2000). Inter-
nal consistency for this study was Cronbach’s alpha = 0.70.
Fatigue
The vitality subscale of the Medical Outcomes Study
36-Item Short-Form Health Survey (MOS-36) was used to
assess fatigue. This subscale has been used to measure
fatigue in people with other chronic diseases (Hewlett et al.
2011, Harel et al. 2012). Participants were asked to
respond to four questions about fatigue during the past
four weeks such as feeling full of pep, worn out, tired and
having a lot of energy. Options for response ranged from 1
(‘all the time’)–6 (‘none of the time’). The vitality subscale
was then calculated, with scores ranging from 0–100.
Higher scores meant participants had more vitality. Test-
retest reliability (r = 092) has been reported for a four-
week interval in people with osteoarthritis (S€oderman &
Malchau 2000). The concurrent validity of the MOS-36
vitality subscale with the Functional Assessment of Chronic
Illness Therapy Scale has been reported (r = 0.65) (Harel
et al. 2012). Internal consistency for the vitality subscale in
this study was Cronbach’s alpha = 0.80.
Outcome variables
Healthcare use
Healthcare use was assessed by telephone interview. Partici-
pants were asked to indicate: (1) the number of nights they
spent in a hospital or other acute care facility; (2) the number
of nights they spent in a rehabilitation hospital, nursing home
or other nonacute care facility; (3) the number of visits to an
ED, triage or urgent care facility; and (4) the number of visits
to a physician assistant, nurse or outpatient clinic in the last
month. The questions addressed all healthcare use, not just
care for COPD. This information was collected at 1, 2, 4, 8
and 10 months after randomisation occurred. The data col-
lected at these time periods were included in our analysis.
Mortality
Vital status was drawn from clinical reports through 31
May 2008 and matched to the Social Security Administra-
tion’s Master Death File. For our study, we analysed data
for five-year mortality.
Other covariates
Demographic and clinical data
Information about age, gender, level of education, marital
status, income, smoking history and current oxygen use at
rest and during sleep was obtained by interview.
Pulmonary function testing
Spirometry was performed with participants seated. The
NETT followed American Thoracic Society guidelines when
conducting pulmonary function tests and single-breath dif-
fusion capacity (American Thoracic Society 1995a,b). Pre-
dicted values for spirometry and diffusion capacity were
used for this analysis (Crapo & Morris 1981, Crapo et al.
1981). Partial pressure of oxygen (PaO2) and partial pres-
sure of carbon dioxide (PaCO2) results, which were col-
lected while participants breathed room air at rest, were
also used for this analysis.
Exercise capacity
Exercise capacity was measured by an electromagnetically
braked cycle ergometer. Participants performed unloaded
pedalling for three minutes at any cadence between 40–70
revolutions/minute (rpm); after 10 minutes of rest, the load
was increased at a rate of 5–10 W every minute while par-
ticipants breathed 30% oxygen (National Emphysema
Treatment Trial Research Group 2003). The test was termi-
nated when the cadence dropped below 40 rpm or when a
staff member terminated the test for safety. Peak workload,
maximum watt on the cycle, was used for this analysis.
Various physiological measures such as breathlessness and
leg muscle fatigue were assessed during the test. Test-retest
reliability of oxygen consumption during a cycle ergometer
test has been reported in people with COPD (reliability
coefficient = 0.97) (Covey et al. 1999).
Quality of life
Quality of life was measured by the MOS-36. This instru-
ment, which consists of 36 items, measures eight compo-
© 2014 John Wiley & Sons Ltd
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nents of health: physical functioning, role-physical, bodily
pain, general health perception, vitality, social functioning,
role-emotional and mental health. The mental component
subscale and physical component subscale were used for
this analysis. The range for each subscale is 0–100. Higher
scores signified better health. Reliability coefficients of the
MOS-36 have been reported (065–094) (McHorney et al.
1994). Further, comparisons of MOS-36 scores among dif-
ferent populations have affirmed the instrument’s construct
validity (McHorney et al. 1993). Cronbach’s alpha was
0.67 for the physical component subscale and 0.63 for the
mental component subscale in this study.
Data analysis
SPSS, version 20.0 (IBM, Armonk, NY, USA) was used to
analyse all data. All continuous variables were expressed as
mean and standard deviation. Categorical variables were
presented as percentage and frequency. Descriptive statistics
were used to describe sample characteristics and study vari-
ables. Symptom scores from the University of California,
San Diego, Shortness of Breath Questionnaire (UCSD), Spiel-
berger State-Trait Anxiety Inventory (STAI), Beck Depres-
sion Inventory (BDI) and Medical Outcomes Study 36-Item
(MOS-36) Short-Form Health Survey were standardised for
our cluster analysis to equalise the effect of the instruments’
different scale lengths. An agglomerative hierarchical cluster
analysis was performed with squared Euclidean distances
used in the proximities matrix, and Ward’s method used as
the clustering method. Agglomerative hierarchical clustering
begins with each symptom as a separate cluster and then
merges symptoms into a larger cluster. Ward’s method was
chosen because it is considered to be superior in decreasing
misclassification of observations (Jain et al. 1986). Our deci-
sion on the appropriate number of cluster solutions was
based on dendrogram and incremental changes in agglomer-
ation coefficients (Ketchen & Shook 1996).
One-way analysis of variance (ANOVA) or chi-square
tests were used to determine whether significant differences
existed among the subgroups of participants in demo-
graphic and clinical characteristics, symptom scores and
outcome measures. Post hoc analyses were conducted using
the Bonferroni procedure to control the overall alpha level
of the six possible pairwise contrasts at 005.
Univariate and multivariate Poisson regression analyses
were used to examine how different subgroups and single
symptoms predict hospital outcomes during 10 months of
follow-up. The results were presented as incidence rate
ratio with 95% CI. Single symptoms were divided into
three groups to compare their effect with the effect of three
symptom cluster subgroups on outcomes. Univariate and
multivariate logistic regression analyses were used to exam-
ine how different subgroups predict mortality at five years
of follow-up. Single symptoms were also entered into logis-
tic regression to examine the relationship between single
symptoms and mortality. We also performed Cox propor-
tional hazard regression to examine the relationship
between mortality and different subgroups. Kaplan–Meier
curves were created to display survival, according to symp-
tom subgroups. A p < 0.05 was considered statistically sig-
nificant.
Results
Cluster and sample characteristics for subgroups
From a sample size of 597, a three-cluster solution
emerged. With the two-cluster solution, 642% of the sam-
ple (n = 383) was categorised in the ‘all low’ subgroup and
358% (n = 214) in the ‘all high’ subgroup (Fig. 1). With
the three-cluster solution, the ‘all low’ subgroup was
divided into two groups, which were ‘all low group’
(n = 192, 323%) and ‘moderate’ subgroup (n = 191,
320%) and ‘all high’ subgroup (n = 214, 358%) (Fig. 1).
Standardised symptom scores for each subgroup (Fig. 2)
show the relatively high level of symptom scores in sub-
group 3 compared with subgroups 1 and 2. Moderate
symptom scores are shown in subgroup 2.
Table 1 presents symptom scores for the three subgroups.
Participants in subgroup 3 had worse dyspnoea, anxiety,
depression and fatigue than those in subgroup 1. All post
hoc analyses that compared symptom scores among the
three subgroups were statistically significant (Table 1).
Final sample
(n = 597)
All low
(n = 383, 64·2%)
All high
(n = 214, 35·8%)
Subgroup 1
All low
(n = 192, 32·2%)
Subgroup 2
Moderate
(n = 191, 32·0%)
Subgroup 3
All high 
(n = 214, 35·8%)
Figure 1 Flow chart for three subgroups.
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Demographic and clinical characteristics (mean age, pro-
portion of higher education and proportion of oxygen use
at rest and during sleep) were significantly different
between subgroups (Table 2). Significant differences in
FEV1% predicted, forced vital capacity (FVC)% predicted,
diffusion capacity of carbon monoxide (DLCO)% pre-
dicted, PaCO2, peak workload on the cycle ergometer and
MOS-36 mental and physical component scales were found
between subgroups (Table 2).
Symptom clusters and healthcare use
ANOVA results showed no difference in the mean number
of nights spent in a hospital or other acute care facility or in
a nonacute care facility and no difference in the number of
visits to an ED, triage or urgent care facility or to a physi-
cian assistant, nurse or outpatient clinic between subgroups
(Table 2). However, Poisson regression analysis showed that
subgroup 3 was more likely to spend more nights in a hospi-
tal or other acute care facility or in a nonacute care facility
and had more visits to a physician assistant, nurse or outpa-
tient clinic than subgroup 1, even after adjusting for other
covariates (Table 3). When analysed by single symptoms,
those with high levels of anxiety, depression or fatigue used
similar healthcare resources as subgroup 3 (Table 3).
Symptom clusters and mortality
Chi-square tests showed that mortality at five-year follow-
up was highest in subgroup 3 (Table 2). In univariate and
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multivariate logistic regression, participants in subgroup 3
were more likely to have died by the five-year follow-up
than participants in subgroups 1 and 2 (Table 4). When
analysed by single symptoms, those with severe dyspnoea
or depression were more likely to have died by the five-year
follow-up (Table 4). Univariate Cox proportional hazards
regression analyses were performed, but no statistical signif-
icance was observed in the survival pattern among sub-
groups. Kaplan–Meier curves presented to display
differences in survival at five-year follow-up, according to
symptom subgroups (Fig. 3).
Discussion
To our knowledge, this is the first study to examine the
relationship of symptom clusters with healthcare use and
mortality in people with COPD. It provides preliminary evi-
dence that high levels of symptoms significantly predicted
healthcare use and mortality in people with severe COPD.
Those with high levels of symptoms, particularly high levels
of anxiety and depression (subgroup 3), were young, less
educated, used oxygen in their daily lives and had severe
COPD, worse exercise capacity and poor quality of life.
Symptom cluster subgroups had more significant relation-
ship with mortality than single symptoms.
Symptom clusters have not been examined extensively in
people with COPD. Previously, the primary author (Park
et al. 2013) examined symptom clusters and the relation-
ship of high symptom burden to outcomes of functional
status and exercise capacity. In that analysis, we observed
two symptom clusters, high and low. Participants with high
levels of symptoms, especially fatigue, were young and less
educated and had worse outcomes. In the current study,
three distinct subgroups emerged, and the difference in the
number of subgroups is because a different method for clus-
ter analysis was used and healthcare use and mortality have
a different relationship with symptoms. Those with high
levels of symptoms, especially high levels of anxiety and
depression, had worse outcomes. A high prevalence of anxi-
ety and depression in people with COPD is well known
and has been reported to be 50–75 and 37–71%, respec-
tively (Solano et al. 2006). Anxiety and depression often
occur together in people with breathing problem (Kunik
et al. 2005). This finding further emphasises that screening
for the presence and levels of anxiety and depression is nec-
essary for people with COPD.
Few demographic characteristics differed among sub-
groups. People in subgroup 3 were younger than people in
subgroup 1. This is consistent with another study that
found that older people had less symptom distress thanT
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younger patients (Degner & Sloan 1995, Kris & Dodd
2004). It may reflect an age-related difference in the percep-
tion of illness and symptoms (Lazarus & DeLongis 1983);
older people might think of symptoms as predictable
events. In our study, people with lower education reported
higher levels of symptoms; this should concern healthcare
providers because a low education level could influence
self-care behaviours for symptom management. As for
health-related quality of life, people in subgroup 3 had poor
quality of life as measured by the mental component scale;
this is reasonable because people in subgroup 3 expressed
higher levels of anxiety and depression than other
subgroups. This likely reflects an overlap in the measures of
symptoms and health-related quality of life.
The observed relationship between symptoms and disease
severity is complex. Subgroup 1 had lower disease severity
reflected by many variables, but the differences between
subgroups were small especially for pulmonary function
tests. Bigger differences were seen for the percentage using
supplemental oxygen, scores on the MOS-36 physical com-
ponent and exercise capacity. The difference in their exer-
cise capacity, subgroup 1 compared to subgroups 2 and 3,
was clinically meaningful (Lacasse et al. 1996). In contrast,
participants in subgroups 2 and 3 had relatively similar
Table 3 Incidence rate ratio (95% CI) for association of symptom clusters and single symptom with number of healthcare use within
10 months
Number of nights
staying in a hospital
Number of nights
staying in a rehab
hospital or other
nonacute care facility
Number of visits to
ER, triage or urgent
care facility
Number of visits to
outpatient clinics or
physician’s assistant
or nurses
Symptom cluster
Unadjusted model
Subgroup 1 1 1 1 1
Subgroup 2 0.84* (0.71–0.99) 186* (123–283) 0.96 (0.67–137) 106 (0.95–119)
Subgroup 3 143* (123–164) 225* (150–335) 119 (0.85–166) 120* (108–134)
Adjusted model†
Subgroup 1 1 1 1 1
Subgroup 2 0.75* (0.62–0.90) 147 (0.94–229) 0.81 (0.54–121) 103 (0.91–116)
Subgroup 3 122* (104–143) 190* (123–293) 0.98 (0.67–144) 112* (100–126)
Dyspnoea‡
Unadjusted model
≤51 1 1 1 1
52–65 170* (144–201) 106 (0.96–119) 133 (0.93–191) 107 (0.96–119)
≥66 166* (141–195) 0.96 (0.87–107) 126 (0.89–179) 0.96 (0.87–107)
Anxiety‡
Unadjusted model
≤26 1 1 1 1
27–36 0.94 (0.80–111) 128 (0.84–194) 129 (0.90–185) 111 (0.99–125)
≥37 124* (106–145) 167* (112–250) 105 (0.72–153) 119* (107–133)
Depression‡
Unadjusted model
≤5 1 1 1 1
6–9 0.51* (0.42–0.61) 0.92 (0.60–141) 0.86 (0.59–124) 0.96 (0.85–107)
≥10 133* (116–153) 149* (101–222) 114 (0.81–159) 120* (109–134)
Fatigue‡
Unadjusted model
≥51 1 1 1 1
31–50 0.92 (0.79–107) 0.73 (0.44–119) 0.84 (0.59–119) 103 (0.93–114)
≤30 128* (110–149) 383* (261–561) 117 (0.83–164) 128* (115–142)
*p < 0.05.
†Covariates include age, gender, race, education level, income level, marital status, pack years of smoking, maximal workload in cycle
ergometer, FEV1% predicted, PaCO2, use of oxygen, physical component scale in MOS-36.
‡Scores were from University of California, San Diego, Shortness of Breath Questionnaire, Spielberger State-Trait Anxiety Inventory, Beck
Depression Inventory and vitality subscale in Medical Outcomes Study 36-Item Short-Form Health Survey.
For this analysis, we used cutpoints that divided the sample into three equal groups for each of the single symptoms.
All analyses were performed separately.
© 2014 John Wiley & Sons Ltd
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disease severity, but subgroup 3 reported more severe symp-
toms, especially anxiety and depression. This finding sug-
gests that the relationship between symptoms and disease
severity is not linear. It appears that as lung function
declines, there reaches a point at which people respond dif-
ferently in terms of their symptom experience. Some experi-
ence a muted response with relatively low levels of
dyspnoea and fatigue, whereas others experience more
intense dyspnoea and fatigue that is accompanied by the
emotional responses of anxiety and depression. The under-
lying mechanisms that account for the differences in
response are not clear, but the difference in symptom bur-
den does have implications for quality of life.
It is well known that the cost of hospital care for people
with COPD is high (National Institutes of Health, National
Heart, Lung, & Blood Institute 2013). Many factors have
been associated with healthcare use in people with COPD,
such as age, body mass index, FEV1, history of hospital
admission for COPD and quality of life (Almagro et al.
2006, Fan et al. 2007, Schembri et al. 2009). Single symp-
toms, especially dyspnoea, have also been significantly asso-
ciated with healthcare use in people with COPD (Fan et al.
2007, Schembri et al. 2009, Papaioannou et al. 2013).
Therefore, it is not surprising that clusters of high levels of
symptoms were found to be significantly associated with
healthcare use compared with low levels of symptoms. Our
finding suggests that managing high levels of symptoms is
necessary to decrease the need for health care in people
with COPD.
Patients with advanced COPD in our study had signifi-
cant mortality. Several factors have been associated with
mortality in people with COPD, including single symptoms,
low FEV1% predicted, body mass index, marital status,
age, oxygen use, lower total lung capacity, previous hospi-
tal admissions, pack years of smoking and quality of life
(Almagro et al. 2002, Yohannes et al. 2002, Martinez et al.
2006, Esteban et al. 2008). It is important to note that sub-
groups 2 and 3 had a higher risk of mortality even after
controlling for FEV1% predicted and a wide range of
demographic variables that are not modifiable. Symptom
clusters are potentially modifiable factors. A better under-
standing of symptom clusters and their relationship to mor-
tality may lead to effective interventions for more vigorous
symptom management to reduce the mortality rate in peo-
ple with COPD.
Table 4 Odds ratios (OR) for association of symptom cluster and
single symptom with five-year mortality from unadjusted and
covariate-adjusted logistic regression modelling
Five-year mortality
Unadjusted OR (95% CI) †Adjusted OR (95% CI)
Symptom cluster
Subgroup 1 1 1
Subgroup 2 151* (101–227) 127 (0.82–199)
Subgroup 3 192* (129–286) 175* (112–274)
Dyspnoea‡
≤51 1
52–65 135 (0.90–203)
≥66 187* (126–279)
Anxiety‡
≤26 1
27–36 108 (0.71–163)
≥37 133 (0.88–201)
Depression‡
≤5 1
6–9 140 (0.91–213)
≥10 190* (128–284)
Fatigue‡
≥51 1
31–50 101 (0.69–148)
≤30 129 (0.86–195)
*p<0.05.
†Covariates include age, gender, race, education level, income level,
marital status, pack years of smoking, FEV1% predicted, PaCO2,
physical component scale in MOS-36 and number of healthcare use.
‡Scores were from University of California, San Diego, Shortness of
Breath Questionnaire, Spielberger State-Trait Anxiety Inventory,
Beck Depression Inventory and vitality subscale in Medical Out-
comes Study 36-Item Short-Form Health Survey.
For this analysis, we used cutpoints that divided the sample into
three equal groups for each of the single symptoms.
All analyses were performed separately.
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Figure 3 Kaplan–Meier curves of five-year survival according to
symptom subgroups (p = 0.09).
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The theory of unpleasant symptoms suggests that the
effects of multiple symptoms may be synergistic (Lenz et al.
1997), but we did not find full support for this. We exam-
ined the relationship between single symptoms and outcomes
and found that symptom cluster subgroups significantly pre-
dicted mortality more than single symptoms, but not with
healthcare use. In previous research (Park et al. 2013), we
examined the effect of single symptoms on other outcomes,
such as functioning and exercise capacity in people with
COPD. In that research, we found that symptom cluster sub-
groups showed a stronger association with social functioning
than single symptoms, but not with physical functioning and
exercise capacity. This indicates that the importance of
symptom clusters may vary depending on the outcome of
interest. Differences in techniques for forming clusters for
single symptoms may also explain some of the observed dif-
ferences in results. Thus, further study is required to test the
theory of unpleasant symptoms in people with COPD.
The major strength of our study was its use of data from
a well-designed randomised study, the NETT. As for its
limitations, no data for comorbidity were available; how-
ever, some studies have shown no association between com-
orbidities and mortality (Esteban et al. 2008). In addition,
we were unable to obtain the entire data for healthcare use
over a 10-month period because the NETT had asked sub-
jects about their healthcare use over the past month at five
time periods, which may have overlooked healthcare use in
the intervening months. Further, we were unable to obtain
detailed information on the reasons for healthcare use: Was
it COPD-related or not? Because information on hospital
care was obtained through self-report, it may not be accu-
rate. Finally, our findings may not be generalisable to peo-
ple with mild-to-moderate COPD.
Conclusion
Three subgroup symptom clusters emerged from four symp-
toms. Our study indicates that the presence of high levels
of symptoms in patients with COPD, especially high levels
of anxiety and depression, was associated with healthcare
use and mortality. Symptom cluster subgroups showed
stronger association with mortality than single symptoms.
This finding suggests that assessing multiple symptoms
rather than a single symptom is important to improve sur-
vival in people with COPD.
Relevance to clinical practice
Patients with high levels of symptoms require greater clini-
cal attention. The assessment of coexisting symptoms
should become part of an initial screening tool for patients
with COPD. Self-monitoring of coexisting symptoms rather
than just individual symptoms should be emphasised in
teaching patients with COPD. Our findings should help
healthcare providers identify patients with COPD who are
at greater risk of adverse outcomes and who could benefit
from an intervention whose aim is to lower hospital admis-
sion rates and mortality. Our findings also stress the impor-
tance of developing more effective symptom interventions
for those with higher levels of symptoms to improve sur-
vival. Targeting modifiable symptoms within the cluster
may be more beneficial than focusing on a single symptom
to improve survival. Further study is needed to examine this
finding in people who reflect the full range of COPD (mild
to severe).
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